Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial

被引：12

作者：

Magnolo, Nina ^{[1
]}

Jaenicke, Thomas ^{[2
]}

Tsianakas, Athanasios ^{[3
]}

Czech, Wolfgang ^{[4
]}

Thaci, Diamant ^{[5
]}

Pinter, Andreas ^{[6
]}

Kerob, Delphine ^{[7
]}

Salah, Samir ^{[7
]}

Luger, Thomas A. ^{[1
]}

机构：

[1] Univ Hosp Munster, Dept Dermatol, Munster, Germany

[2] IUF, Leibniz Res Inst Environm Med, Dusseldorf, Germany

[3] Fachklin Bad Bentheim, Dept Dermatol, Bad Bentheim, Germany

[4] Goethe Univ Frankfurt, Dermatol & Allergol Clin, Frankfurt, Germany

[5] Univ Lubeck, Inst Comprehens Ctr Inflammat Med, Lubeck, Germany

[6] Univ Hosp Frankfurt, Clin Dermatol Venereol & Allergol, Frankfurt, Germany

[7] Roche Posay Lab Dermatol, Levallois-perret, France

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷

关键词：

EUROPEAN GUIDELINES; BARRIER FUNCTION; TASK-FORCE; CHILDREN; EMOLLIENTS; ADULTS; MICROBIOME; EFFICACY; LIFE;

D O I：

10.1111/jdv.18949

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

BackgroundModerate to severe AD can be successfully managed by systemic treatments. Current guidelines also recommend emollients or emollients 'plus' and eudermic cleansers for all AD patients to improve the skin barrier and provide anti-irritant and anti-pruritic effects. ObjectivesTo investigate the efficacy of skin care (in addition to systemic treatment) with an Emollient 'plus' balm designed to improve the skin barrier and skin microbiome plus a corresponding syndet compared to usual commercial emollients and cleansers. MethodsIn a randomized controlled multicenter study, patients with moderate to severe AD (Severity scoring of atopic dermatitis [SCORAD] score >= 40) receiving systemic treatment (cyclosporin A, dupilumab or a Janus kinase inhibitor) were randomized 1:1 to apply twice daily for 10 weeks Emollient 'plus' after pre-cleaning with the syndet (Emollient 'plus' group) or to continue with their usual emollient and cleanser (Control group). Assessments included SCORAD, pruritus on a Visual Analog Scale, Dermatology quality of life questionnaire (DLQI), efficacy and tolerance questionnaires. ResultsIncluded were 57 patients with mean age of 38 years (range 19-70 years). The mean amount of emollient used after 10 weeks was 447.3 g (range 29-1099 g) and 613.2 g (range 97-2565 g) for the Emollient 'plus' versus the Control, respectively (p = 0.0277). After 10 weeks, subjects in the Emollient 'plus' had a significantly greater reduction in current pruritus (p = 0.0277) and a greater reduction in some DLQI items compared to the Control group. ConclusionsIn patients with moderate to severe AD receiving systemic treatment, the Emollient 'plus' regimen significantly improved pruritus and quality of life items compared to the control, while using 23% less product over a 10-week period. These results stress the importance of daily use of emollients, especially emollients 'plus' to improve signs, symptoms and quality of life in patients with AD.

引用

页码：18 / 26

页数：9

共 28 条

[1] Epidemiology of atopic dermatitis in adults: Results from an international survey [J].